SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Trump Says Anthropic No Longer Seen as National Security Threat 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
SEATTLE, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that it will conduct a conference call on Tuesday, December 8, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss new clinical data from ongoing clinical trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer. The data, which include additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive metastatic breast cancer, as well as an analysis of patients who suffer from central nervous system (CNS) metastases, are slated for presentation during the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon’s website at www.oncothyreon.com. An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website.
About Oncothyreon
Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
CONTACT: Investor Relations: Julie Rathbun Rathbun Communications 206-769-9219 [email protected] Media Relations: Kelly France, Ph.D. BrewLife 415-946-1076 [email protected]
